The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan

作者
Toshihiko Aranishi,Ataru Igarashi,Kazuo Hara,Beatrice Osumili,Zhihong Cai,Aska Mizogaki,Manaka Sato,Masakazu Takeuchi,Alice Minghetti,Barnaby Hunt,Takashi Kadowaki
出处
期刊:Diabetes Therapy [Adis, Springer Healthcare]
卷期号:16 (3): 431-445 被引量:2
标识
DOI:10.1007/s13300-024-01675-7
摘要

INTRODUCTION: This analysis aimed to evaluate the long-term cost-effectiveness of tirzepatide 5 mg versus dulaglutide 0.75 mg (both administered once weekly) in people not achieving glycemic control on metformin, based on the results of the head-to-head SURPASS J-mono trial from a Japanese healthcare payer perspective. METHODS: A cost-utility analysis was performed over a 50-year time horizon using an implementation of the UKPDS Outcomes Model 2 developed in Microsoft Excel. Baseline cohort characteristics, treatment effects and adverse event rates were sourced from the SURPASS J-mono trial. Simulated patients were assumed to receive either tirzepatide 5 mg or dulaglutide 0.75 mg until HbA1c exceeded 8.0%, at which point treatment was discontinued and basal insulin was initiated. Direct costs were derived from the Japan Medical Data Center claims database. Future costs and clinical benefits were discounted at 2% annually. RESULTS: In this cost-utility modeling analysis, tirzepatide 5 mg was associated with lower diabetes-related complication rates, improved life expectancy, improved quality-adjusted life expectancy and higher direct costs versus dulaglutide 0.75 mg. This resulted in an incremental cost-effectiveness ratio (ICER) of JPY (Japanese yen) 1,302,240 per quality-adjusted life year (QALY) gained for tirzepatide 5 mg versus dulaglutide 0.75 mg (JPY 140 = USD 1). Tirzepatide remained cost-effective versus dulaglutide over a range of sensitivity analyses. CONCLUSIONS: In this analysis, tirzepatide 5 mg was associated with an ICER below the commonly quoted willingness-to-pay threshold of JPY 5,000,000 per QALY gained, suggesting that tirzepatide is a cost-effective treatment option for adult patients with type 2 diabetes mellitus, compared with dulaglutide 0.75 mg.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
致远完成签到 ,获得积分10
1秒前
Firsterchao发布了新的文献求助30
2秒前
2秒前
2秒前
zzz发布了新的文献求助10
2秒前
Zz发布了新的文献求助10
3秒前
3秒前
syvshc完成签到,获得积分0
4秒前
bkagyin的应助被Kiki采纳,获得10
4秒前
涛涛完成签到,获得积分10
5秒前
自觉花生发布了新的文献求助10
5秒前
危险的鲅鱼完成签到 ,获得积分10
6秒前
雯雯完成签到,获得积分10
6秒前
华仔的应助被弗耒earth采纳,获得10
6秒前
cliche完成签到,获得积分10
6秒前
7秒前
9秒前
berg发布了新的文献求助10
11秒前
12秒前
小刘的应助被端庄的夏寒采纳,获得10
12秒前
庾傀斗发布了新的文献求助10
13秒前
123发布了新的文献求助20
14秒前
完美世界的应助被郭娅楠采纳,获得10
14秒前
15秒前
溜溜完成签到 ,获得积分10
15秒前
15秒前
大知闲闲发布了新的文献求助10
16秒前
共享精神的应助被Han采纳,获得10
16秒前
???完成签到,获得积分10
17秒前
RegSequ完成签到,获得积分10
18秒前
和谐完成签到 ,获得积分10
18秒前
younger发布了新的文献求助10
18秒前
19秒前
爆米花的应助被yang采纳,获得10
19秒前
19秒前
Orange的应助被zjy147采纳,获得10
19秒前
Hao完成签到,获得积分10
20秒前
20秒前
mumu完成签到 ,获得积分10
21秒前
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186629
求助须知:如何正确求助?哪些是违规求助? 9574913
关于积分的说明 21838832
捐赠科研通 7784206
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559183
邀请新用户注册赠送积分活动 2481582